LGND Живые сигналы | Максимизируйте прибыль с Getagraph.com

Продать 105086 min ago

@ $73.34

Выпущен: 14 февр. 2024 @ 18:26

Доходность: -3.78%

Предыдущий сигнал: февр. 13 - 17:30

Предыдущий сигнал: Купить

Доходность: -1.89 %

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...

Stats
Объем за сегодня	85 640.00
Средний объем	173 217
Рыночная капитализация	1.25B
EPS	$0 ( 2024-02-27 )
Дата следующего отчета о доходах	( $1.130 ) 2024-05-02
Last Dividend	$0.456 ( 2010-07-02 )
Next Dividend	$0 ( N/A )
P/E	23.29
ATR14	$0.125 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Kozarich John W	Buy	2 893	Common Stock
2024-04-24	Kozarich John W	Sell	2 893	Non-Qualified Stock Option (right to buy)
2024-03-25	Davis Todd C	Buy	3 556	Common Stock
2024-03-25	Davis Todd C	Buy	2 156	Common Stock
2024-03-25	Davis Todd C	Buy	2 855	Common Stock

INSIDER POWER
76.80
Last 99 transactions
Buy: 847 979 \| Sell: 102 779

Объем Корреляция

Длинно: -0.41 (neutral)

Кратко: 0.43 (neutral)

Signal:(43.193) Neutral

Ligand Pharmaceuticals Корреляция

10 Самые положительные корреляции
ALSK	0.829
NVEC	0.811

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Ligand Pharmaceuticals Корреляция - Валюта/Сырье

-0.42
( neutral )

-0.50
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.34
( neutral )

0.48
( neutral )

Ligand Pharmaceuticals Финансовые показатели

Annual	2023
Выручка:	$131.31M
Валовая прибыль:	$119.75M (91.20 %)
EPS:	$3.02

FY	2023
Выручка:	$131.31M
Валовая прибыль:	$119.75M (91.20 %)
EPS:	$3.02

FY	2022
Выручка:	$196.25M
Валовая прибыль:	$143.42M (73.08 %)
EPS:	$-0.310

FY	2021
Выручка:	$277.13M
Валовая прибыль:	$214.96M (77.56 %)
EPS:	$2.22

Financial Reports:

No articles found.

Ligand Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.02 - good (80.23%) | Divividend Growth Potential Score: 1.515 - No dividend growth expected in the near future

Information

First Dividend	$9.36	2007-04-03
Last Dividend	$0.456	2010-07-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$9.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.65	--
Div. Sustainability Score	8.02
Div.Growth Potential Score	1.515
Div. Directional Score	4.77	--

Next Divdend (Est)
(2026-09-30)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2007	$9.36	14.30%
2008	$0	0.00%
2009	$0	0.00%
2010	$0.456	3.50%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.378	1.500	2.44	3.66	[0 - 0.5]
returnOnAssetsTTM	0.0596	1.200	8.01	9.62	[0 - 0.3]
returnOnEquityTTM	0.0742	1.500	-0.287	-0.431	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	14.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	12.49	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.368	1.500	3.51	5.27	[0.2 - 2]
debtRatioTTM	0.00740	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	2.60	1.000	-0.148	-0.148	[3 - 30]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.245	2.00	-0.122	-0.245	[0 - 20]
debtEquityRatioTTM	0.00880	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.920	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.0666	1.000	-0.669	-0.669	[0.1 - 0.6]
cashFlowToDebtRatioTTM	8.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.158	0.800	-2.28	-1.826	[0.5 - 2]
Total Score				8.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.83	1.000	7.59	0	[1 - 100]
returnOnEquityTTM	0.0742	2.50	-0.185	-0.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.245	2.00	-0.0815	-0.245	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0118	1.500	-3.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.378	1.000	3.06	0	[0.1 - 0.5]
Total Score				1.515

Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Обновления в реальном времени для Ligand Pharmaceuticals [LGND]

Upcoming Earnings Alert

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)